Co-Diagnostics

Co-Diagnostics FCF Growth

The Year-over-Year Free Cash Flow Growth of Co-Diagnostics (CODX) as of Nov 20, 2026 is 0.22 %. In the previous year, Year-over-Year Free Cash Flow Growth was -27.54 % — a change of -100.81% (higher).

FCF Growth

0.22 %

YoY

-100.81%

Last updated:

Year-over-Year Free Cash Flow Growth of Co-Diagnostics is 2025 0.22 % . Year-over-Year Free Cash Flow Growth of Co-Diagnostics was 2024 -27.54 % . It decreases by -100.81% higher compared to the previous year.

The Co-Diagnostics FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-23.37 USD
Jan 1, 2019
-36.81 USD
Jan 1, 2020
585.80 USD
Jan 1, 2021
47.54 USD
Jan 1, 2022
-87.28 USD
Jan 1, 2023
-556.06 USD
Jan 1, 2024
-27.54 USD
Jan 1, 2025
0.22 USD
The Co-Diagnostics FCF Growth history
YEARFCF GrowthYoY
0.22 %-100.81%
-27.54 %-95.05%
-556.06 %+537.12%
-87.28 %-283.60%
47.54 %-91.88%
585.80 %-1,691.52%
-36.81 %+57.51%
-23.37 %-84.65%
-152.22 %-873.88%
19.67 %-125.90%
-75.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Year-over-Year Free Cash Flow Growth of Co-Diagnostics is 0.22 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Co-Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Co-Diagnostics

All Key Metrics — Co-Diagnostics